Live·Verified funding discovery · 2026.2
874 grants · 19 open · 435 companies · 2640 concepts874 / 19 / 435 / 2640
△COMPANIESCompanies rated · 435 (no change)△PROJECTSProjects rated · 70 (no change)△CATALOGUE874 grants in catalogue · 19 open right now•POWERED BYOpen Longevity · 501(c)(3) · Sherman Oaks, CA△COMPANIESCompanies rated · 435 (no change)△PROJECTSProjects rated · 70 (no change)△CATALOGUE874 grants in catalogue · 19 open right now•POWERED BYOpen Longevity · 501(c)(3) · Sherman Oaks, CA
← ← Back to projectsDrug & Molecule Discovery →

Team GlyNAC

Drug & Molecule DiscoveryLast rated 5/25/2026UniversityCanonical source ↗

Team GlyNAC appears to be a Baylor College of Medicine-associated translational longevity project built around GlyNAC, a glycine plus N-acetylcysteine supplementation strategy intended to raise glutathione and improve mitochondrial and oxidative-stress-related aging defects. The evidence base is suggestive but still limited: there are pilot and randomized older-adult studies reporting improvements in biomarkers and some functional measures, plus mouse studies reporting lifespan, cognition, and cardiac effects, but much of the accessible material is Baylor news coverage, small early-stage studies, or preclinical work, with human durability, safety, and hard clinical outcomes still unresolved.

Source coverage

17 sources searched, 153 evidence rows (138 with full text)
Team project0Project page1Project page crawl6PubMed7Semantic Scholar0OpenAlex7arXiv0bioRxiv0Web search7News13YouTube11Wikipedia20GitHub0Author publications0Organization records0Patents (project-held)2Patents (field corridor)38
Non-commercial entity

This project is run by a university research project. Any funding here takes the form of a grant, donation, or public contract — not equity. There is no financial return expected.Team GlyNAC is described as a Baylor College of Medicine-associated project, and Baylor is an academic college rather than a company or standalone institute.

Scientific

Mechanism and evidence quality

56.8

Breakthrough

How much success could unlock

51.9

Investor

Deal-quality signals

52.2

Overall

Weighted composite

53.7

Where this project sits

Positioned against every public project across all sections

0255075100048121620LIFESPAN GAIN (YEARS, ESTIMATED)OVERALL SCOREmax in DB: 15 yrTeam GlyNAC
BioreplacementBioinformationDrug & Molecule DiscoveryGenetic & Cellular TherapiesAging Biology ResearchDiagnostics & BiomarkersBrain & Cognitive LongevityResearch & Funding Infrastructure
Inner ring · capital to breakeven  ·  Outer ring · best-case upside multiple

Comprehensive brief

Hypothesis

If age-related glutathione deficiency is a causal driver of oxidative stress, mitochondrial dysfunction, inflammation, and downstream physical and cognitive decline, then GlyNAC supplementation can restore glutathione biology and improve healthspan-related function in older adults.

Mechanism

The proposed mechanism is nutritional precursor loading: glycine plus N-acetylcysteine increases glutathione synthesis, which is then claimed to reduce oxidative stress, improve mitochondrial function and mitophagy, lower inflammation and insulin resistance, and in some studies improve tissue-specific defects in brain, heart, liver, and kidney. This mechanism is biologically plausible within the project’s own evidence base, but the strongest mechanistic support remains preclinical.

Approach

The approach is a translational supplementation program centered on GlyNAC in older adults and related populations, supported by mouse mechanistic studies. Evidence includes a 2021 pilot clinical trial in older adults, a later randomized clinical trial in older adults, smaller proof-of-concept work in type 2 diabetes and HIV populations, and mouse studies on lifespan, cognition, and cardiac aging. The program is therefore closer to an early therapeutic intervention effort than to basic aging biology alone.

Status

Status is early clinical and preclinical, not validated. Human evidence consists mainly of small pilot or early randomized studies with reported biomarker and functional improvements, while the most dramatic claims such as 24% lifespan extension come from mice. A larger randomized clinical trial was described as planned in Baylor coverage, and some 2024 title-level signals suggest continuing human work, but the provided evidence does not establish a definitive late-stage clinical program or confirmed XPRIZE outcome from a strong primary source.

Success criteria

Convincing success would require independently replicated randomized controlled trials in older adults showing clinically meaningful improvements, not just biomarker shifts, with clear sample sizes, effect sizes, durability, and safety reporting. Stronger evidence would also need to resolve whether benefits generalize across sexes, since a 2025 mouse cardiac-aging paper reported benefit in old male mice but not females, with worse exercise performance in females.

Near-term impact (1-3 yrs)

If the central claim is validated in the next 1-3 years, the most practical applications would be a relatively simple older-adult supplementation intervention aimed at improving physical function, gait or exercise tolerance, blood-pressure or metabolic-risk markers, and possibly some aspects of cognitive aging. It could also support targeted trials in populations already discussed in the evidence, such as older adults with metabolic dysfunction, HIV-associated premature-aging phenotypes, or biomarker-defined oxidative-stress states.

Future horizons (5-20 yrs)

If the project succeeds over 5-20 years, it could open a larger subfield around precursor-based restoration of glutathione metabolism as a tractable longevity intervention class, including combination therapies, stratified use by oxidative-stress or mitochondrial phenotype, and organ-specific aging programs for brain, heart, and metabolic disease. It could also shift some aging research toward low-cost metabolic repletion strategies, but only if long-term human data show benefits beyond transient biomarker improvement.

Breakthrough thesis

The strongest upside case is that GlyNAC is a cheap, scalable, mechanistically coherent intervention that treats an upstream metabolic bottleneck in aging rather than a single disease endpoint, allowing one supplementation strategy to improve multiple aging hallmarks and practical function in humans.

Failure thesis

The main failure case is that the project is over-extrapolating from small studies, institutional news coverage, and mouse data: biomarker improvements may not translate into durable clinical benefit, lifespan effects may be species-specific, sex-dependent responses may complicate generalization, and Baylor’s patent/licensing position creates conflict-of-interest pressure around interpretation.

Risk of failure

Technical72

The biology is plausible and there is some human signal, but the evidence base still looks early and fragile. The strongest positive evidence is a randomized clinical trial in older adults and an earlier pilot study, yet the largest efficacy claims remain distributed across biomarkers, functional measures, and preclinical mouse lifespan work rather than hard clinical outcomes. A newer cardiac-aging mouse paper also found benefit in old males but not females, which raises concern that the mechanism may not be robust across contexts.

Translational79

Translational risk is high because the project still leans heavily on mouse and small-cohort human evidence. The mouse data report lifespan and tissue-level effects, while the human studies are in older adults but remain early-stage and relatively small. Generalization is also uncertain: a separate randomized controlled trial in healthy older adults focused on redox endpoints, not broad healthspan outcomes, and the sex-dependent cardiac-aging result in mice suggests subgroup effects could matter materially in humans.

Regulatory / jurisdictional46

Regulatory risk is moderate rather than extreme. GlyNAC uses familiar nutritional ingredients and has already been studied in randomized older-adult trials, which lowers basic feasibility risk. But the project is trying to connect a supplement-like intervention to aging, mitochondrial dysfunction, and broad therapeutic claims, and the patent estate shows medical-use positioning rather than simple commodity supplementation. That creates pathway ambiguity: easier to sell as a supplement, harder to substantiate as a regulated anti-aging or disease-modifying therapy.

Competitive dynamics69

Competitive risk is substantial because the approach is not obviously proprietary at the modality level. Multiple patent families around glycine/NAC combinations and adjacent glutathione-enhancement compositions are already associated with Baylor, Nestle, or other parties, and Nestle-linked authors also published a randomized controlled trial in healthy older adults. That suggests the field is crowded enough that freedom to operate and commercialization leverage may narrow even if the biology proves real.

Team / operational82

Operational risk is high because the project-specific evidence here says very little about the actual operating team. The only direct project-specific Baylor source provided is effectively a generic BCM page on the Baylor domain, which weakly supports institutional affiliation but does not establish a defined company, management bench, financing base, execution roadmap, or de-risked delivery plan. That lack of project-specific execution evidence forces a skeptical score.

Funding / capital57

Capital risk looks moderate. Compared with a novel biologic, this is a simpler nutritional intervention and early human studies have already been run, so the path is not maximally capital intensive. But the current evidence is still small-study and early-stage; proving durable healthspan benefit in older adults would likely require larger, longer randomized trials, which are expensive and hard to finance for a common-ingredient intervention with imperfect exclusivity.

Scientific panel

Mechanism plausibility68

The core mechanism is plausible: GlyNAC supplies glycine and N-acetylcysteine as glutathione precursors, and the cited human and mouse papers tie supplementation to glutathione deficiency, oxidative stress, mitochondrial dysfunction, inflammation, and physical-function or cognition-related endpoints. The weakness is that this does not prove glutathione deficiency is an upstream causal driver of broad human aging rather than a correlated, modifiable biomarker. The sex-difference mouse heart paper also cautions that organ and sex context may matter.

Evidence base57

There is more than pure preclinical speculation: evidence includes a randomized older-adult clinical trial, a pilot older-adult clinical trial, mouse lifespan and cognition studies, and smaller disease-context studies in type 2 diabetes and HIV. However, the strongest human evidence appears early, small, and biomarker-heavy, while lifespan claims are mouse-based. The independent healthy-older-adult RCT appears focused on glutathione redox and oxidative damage rather than broad healthspan outcomes, which limits confidence in translation.

Methodological rigor52

The presence of a randomized clinical trial in older adults and an independent randomized controlled trial of glycine/NAC supports moderate rigor. Still, the accessible evidence does not establish large sample sizes, preregistration, hard clinical endpoints, durable follow-up, or strong correction for many measured outcomes. Several supporting studies are explicitly pilot or open-label, and much of the mechanistic breadth comes from preclinical or surrogate measurements.

Reproducibility38

The program has repeated signals across Baylor-authored human and mouse studies, but that is mostly within a connected investigator ecosystem. Independent replication of the full healthspan claim is weak: the outside RCT addresses redox/oxidative-damage status, not the broad functional aging package, and the 2025 mouse cardiac-aging paper reports sex-specific benefit rather than uniform replication. Reproducibility is therefore suggestive but not yet robust.

Novelty48

The specific GlyNAC translational package is somewhat distinctive in combining two old, low-cost precursors and targeting aging hallmarks, but the broader space of amino-acid, glutathione, antioxidant, and mitochondrial supplements is crowded. Multiple patents and products around glycine, NAC, glutathione, amino acids, and mitochondrial dysfunction imply the project is more incremental translational refinement than a new modality.

Falsifiability74

The central claim is testable: randomized trials can measure whether GlyNAC raises glutathione, lowers oxidative-stress and mitochondrial-dysfunction markers, and improves prespecified physical or cognitive outcomes versus placebo. Mouse lifespan, brain, and heart studies also define concrete endpoints that could fail. The main caveat is that very broad aging-hallmark framing can become hard to falsify unless trials predefine primary outcomes and clinically meaningful effect sizes.

Breakthrough panel

Mechanism novelty42

GlyNAC is a plausible but not highly novel mechanism: precursor loading with glycine plus N-acetylcysteine to restore glutathione and downstream mitochondrial/oxidative-stress biology. The project-specific patent record supports an identifiable Baylor-linked GlyNAC IP position, but the broader evidence also shows many adjacent amino-acid, glutathione, and mitochondrial-dysfunction approaches, so this looks more like a refined translational variant than a new biological paradigm.

Effect size+2 yr lifespan★55

The upside is nontrivial because the cited human GlyNAC RCT and pilot titles report improvements across glutathione deficiency, oxidative stress, mitochondrial dysfunction, inflammation, physical function, muscle strength, and cognition, and the mouse paper reports increased length of life. Skeptically, the strongest lifespan signal is preclinical, while human evidence is still early, biomarker-heavy, and not yet hard-outcome longevity proof. I estimate a successful human healthspan/lifespan impact around 2 years, not a radical rejuvenation effect.

Cross-domain impact45

The approach could affect adjacent domains where glutathione, mitochondrial dysfunction, inflammation, cognition, metabolic health, and physical function overlap, including diabetes, HIV-associated aging phenotypes, brain aging, and possibly cardiac aging. But the current support is mostly early clinical or mouse work, and one aging-heart paper reports sex-specific benefit, limiting confidence in broad transferability right now.

Future opening potential58

If the human results replicate, GlyNAC could open a practical class of low-cost metabolic repletion interventions and stratified trials around oxidative-stress or mitochondrial-defect phenotypes. The long-term opening is meaningful because the intervention is simple and scalable, but it is bounded by the fact that glutathione/antioxidant and amino-acid supplementation are already crowded areas rather than a wholly new platform.

Time horizon~3 yr★72

Demonstrable results are relatively near-term because human pilot and randomized clinical work already exists, and additional healthspan competition activity is visible through XPRIZE milestone coverage. The reason this is not higher is that decisive clinical validation, durability, sex-generalizability, and hard outcomes still require larger independent trials.

Paradigm shift signal48

If GlyNAC robustly improves multiple aging hallmarks and functional outcomes in humans, it would challenge skepticism that simple nutritional precursor therapy can materially alter aging biology. Still, it would not overturn the field as strongly as partial reprogramming, senolytics, or regenerative replacement; it would mainly strengthen a metabolic-restoration view of healthspan intervention.

Investor panel

Most attractive
Addressable market (78)

Large aging/healthspan market, but TAM is weakly anchored: cited field context says older adults are expected to exceed 2.1B by 2050 and life-extension/anti-aging products are already a large commercial category. I use $50B as a conservative historical anti-aging-products anchor, not a validated GlyNAC-specific market.

Most concerning
Founder skin in the game (20)

No fetched project-specific evidence shows founder/PI personal capital, salary sacrifice, equity ownership, public founder risk, or other strong skin-in-game signals. Academic reputation risk exists only as an inference and is not scored heavily.

Addressable market$50B★78

Large aging/healthspan market, but TAM is weakly anchored: cited field context says older adults are expected to exceed 2.1B by 2050 and life-extension/anti-aging products are already a large commercial category. I use $50B as a conservative historical anti-aging-products anchor, not a validated GlyNAC-specific market.

Defensibility42

Some IP exists around NAC plus glycine improving glutathione, with Baylor listed among assignees on granted/published patent families. Defensibility is limited because glycine and NAC are commodity ingredients, adjacent Nestle and other patent activity exists, and a COVID-related Baylor GlyNAC application is listed as ceased.

Team execution capacity56

The strongest project-specific evidence only establishes Baylor College of Medicine context and institutional clinical/research infrastructure. The broader GlyNAC paper trail indicates repeated human and mouse studies, but those rows are field_context and are therefore discounted for this execution dimension.

Founder skin in the game20

No fetched project-specific evidence shows founder/PI personal capital, salary sacrifice, equity ownership, public founder risk, or other strong skin-in-game signals. Academic reputation risk exists only as an inference and is not scored heavily.

Customer validation signal38

There is some outside validation signal from XPRIZE Healthspan milestone-winner coverage at the competition level, but the provided excerpt does not specifically name Team GlyNAC. Human studies imply participant recruitment, but those are field_context and cannot be used here as customer validation under the rubric. No LOIs, paying customers, pharma options, or FDA designations are shown.

Burn to breakeven$35M★72

If developed as a supplement, GlyNAC is likely capital efficient because the active components are inexpensive, orally administered, and already familiar nutraceutical ingredients. However, proving disease/healthspan claims with credible randomized trials still requires meaningful clinical spend. Estimate $35M to break even, anchored below typical biotech because commercialization could be supplement-led rather than full drug approval.

Time to value3 yr★68

Near-term value could come from supplement commercialization or XPRIZE/clinical-readout milestones faster than a full therapeutic approval. I estimate 36 months to a material readout or commercial value event, but durable clinical validation remains unresolved.

Regulatory pathway clarity45

Route clarity depends on claims: a dietary supplement path is straightforward for structure/function marketing, but healthspan, cognition, frailty, or disease-modification claims would need much clearer FDA endpoints. Existing human RCT evidence helps, but there is no fetched evidence of FDA designation, agreed endpoint, or late-stage trial path.

Competitive freedom35

Competitive freedom is constrained. The evidence shows multiple overlapping patent families around glycine/NAC/NAD precursors, glutathione enhancement, mitochondrial dysfunction, amino-acid supplementation, and muscle/aging use cases, including Nestle and other assignees. Commodity ingredients further reduce room to own the category.

Asymmetric upside100×★73

The upside case is large if a cheap oral intervention reproducibly improves physical function, cognition, mitochondrial defects, and lifespan/healthspan biology. Human evidence includes pilot and randomized older-adult studies, while lifespan extension remains mouse-level. That supports high but not breakthrough-biotech-level asymmetry.

Exit landscape30

No fetched evidence provides verified M&A or licensing deal comparables for GlyNAC-like healthspan supplements. Patent activity and broad longevity interest suggest potential strategic interest, but the evidence does not establish a strong exit market with priced comps.

Cost to commercialize$20M★76

Commercial launch as a supplement should be far less capital intensive than a novel drug: oral formulation, commodity inputs, and no bespoke manufacturing platform are apparent. The score is reduced because credible healthspan positioning likely requires larger RCTs and safety/durability work.

Authors

No authors resolved yet.

Scientific theories

GlyNAC reversal of mitochondrial aging defectsPrimarymanual entrymedium

GlyNAC is claimed to affect aging and healthspan by reversing multiple aging-associated cellular defects, with mitochondrial dysfunction identified as the primary defect. The causal theory is that restoring or correcting mitochondrial function through GlyNAC treatment should improve biological features of aging and thereby support healthier aging. Testable predictions are that aged subjects receiving GlyNAC should show measurable improvement in mitochondrial function compared with baseline or untreated aged controls, and that these mitochondrial improvements should coincide with reversal of additional aging-related defects and improvements in healthspan-relevant outcomes.

Popperian evaluation
Premise plausibility6.0/10

The theory starts from a biologically credible premise that mitochondrial dysfunction is associated with aging and could contribute causally to age-related decline. It is also plausible that restoring redox balance or related metabolic capacity could affect mitochondrial function. However, the stronger claim that mitochondrial dysfunction is the primary aging defect and that GlyNAC can correct it sufficiently to reverse multiple aging-associated defects is under-supported in the provided evidence context.

Supporting
  • Mitochondrial dysfunction is explicitly identified as the central defect targeted by the theory.
  • The theory includes a coherent mechanistic chain from GlyNAC treatment to mitochondrial improvement to broader biological and healthspan effects.
Counter
  • No publications or direct experimental evidence are provided in the evidence context.
  • The claim that mitochondrial dysfunction is primary, rather than one interacting feature among many aging processes, is asserted rather than demonstrated.
  • The theory depends on the assumption that GlyNAC can restore mitochondrial function strongly enough to affect organism-level aging phenotypes.
Explanatory power4.0/10

The theory could explain a pattern in which GlyNAC improves mitochondrial measures and multiple aging-related phenotypes together. But with no cited observations or comparative evidence, it is unclear whether it explains known data better than alternatives such as general antioxidant effects, improved glutathione availability, changes in inflammation, nutrition-related effects, placebo effects, or nonspecific metabolic improvement.

Supporting
  • The theory links mitochondrial recovery with reversal of additional aging-related cellular defects and healthspan-relevant outcomes.
  • It offers a causal explanation rather than only a descriptive association.
Counter
  • The provided context contains no observed results to explain.
  • Alternative explanations are not ruled out or directly compared.
  • Coincident improvement in multiple biomarkers would not by itself establish mitochondrial correction as the primary causal driver.
Falsifiability8.0/10

The theory makes concrete, testable predictions: aged subjects treated with GlyNAC should show measurable mitochondrial improvement versus baseline or aged controls, and those improvements should coincide with reversal of other aging defects and healthspan-relevant outcomes. It could be weakened or falsified if controlled studies showed no mitochondrial improvement, no downstream aging-related improvements, or healthspan benefits without mitochondrial correction.

Supporting
  • The theory predicts measurable improvement in mitochondrial function after GlyNAC treatment.
  • It predicts comparison against baseline or untreated aged controls.
  • It predicts that mitochondrial changes should coincide with broader cellular and healthspan-relevant improvements.
Counter
  • Some terms remain broad, such as biological features of aging and healthspan-relevant outcomes.
  • The theory would be more falsifiable if it specified exact mitochondrial assays, effect sizes, time windows, and required downstream outcomes.
Ambition8.0/10

The theory is ambitious because it attempts to address a central aging problem: whether correcting a core cellular defect can reverse broader aging biology and improve healthspan. The mechanism is bold in assigning mitochondrial dysfunction a primary causal role and proposing GlyNAC as an intervention capable of reversing multiple defects. Its novelty and ambition are high, though somewhat limited by the breadth of the claim and lack of detailed mechanistic specificity in the provided context.

Supporting
  • The theory targets aging and healthspan rather than a narrow biomarker change.
  • It proposes reversal of multiple aging-associated cellular defects through a mitochondrial-centered mechanism.
  • It treats mitochondrial dysfunction as a primary causal defect rather than a downstream correlate.
Counter
  • The mechanism is broad and does not specify precisely which mitochondrial defects are corrected or how this drives each downstream aging phenotype.
  • Without stronger evidence, the claim risks being more programmatic than mechanistically distinctive.
Foundational alignment
thermodynamics · aligned (7)network theory · tension (4)evolution · tension (3)cybernetics · tension (4)disease etiology · tension (4)
Theory rollup
Premise plausibility6.0/10

The theory starts from a biologically credible premise that mitochondrial dysfunction is associated with aging and could contribute causally to age-related decline. It is also plausible that restoring redox balance or related metabolic capacity could affect mitochondrial function. However, the stronger claim that mitochondrial dysfunction is the primary aging defect and that GlyNAC can correct it sufficiently to reverse multiple aging-associated defects is under-supported in the provided evidence context.

Explanatory power4.0/10

The theory could explain a pattern in which GlyNAC improves mitochondrial measures and multiple aging-related phenotypes together. But with no cited observations or comparative evidence, it is unclear whether it explains known data better than alternatives such as general antioxidant effects, improved glutathione availability, changes in inflammation, nutrition-related effects, placebo effects, or nonspecific metabolic improvement.

Falsifiability8.0/10

The theory makes concrete, testable predictions: aged subjects treated with GlyNAC should show measurable mitochondrial improvement versus baseline or aged controls, and those improvements should coincide with reversal of other aging defects and healthspan-relevant outcomes. It could be weakened or falsified if controlled studies showed no mitochondrial improvement, no downstream aging-related improvements, or healthspan benefits without mitochondrial correction.

Ambition8.0/10

The theory is ambitious because it attempts to address a central aging problem: whether correcting a core cellular defect can reverse broader aging biology and improve healthspan. The mechanism is bold in assigning mitochondrial dysfunction a primary causal role and proposing GlyNAC as an intervention capable of reversing multiple defects. Its novelty and ambition are high, though somewhat limited by the breadth of the claim and lack of detailed mechanistic specificity in the provided context.

Videos

Can This Hidden Supplement Keep You Young Forever? - YouTube
low signal
5:16953 views38 likes3 commentsnot applicableField context

Video summary pending.

Activating Autophagy With Spermidine While Growing Muscle
discussed
10:1314,236 views501 likes72 commentsnot applicableField context

Video summary pending.

The Importance Of Maintaining Glutathione As We Age - YouTube
discussed
5:397,883 views435 likes65 commentsnot applicableField context

Video summary pending.

NAC: A Cancer causing Downfall? - YouTube
discussed
6:29141,203 views5,969 likes756 commentsnot applicableField context

Video summary pending.

Are Urolithin A Longevity Supplements worth your Money ... - YouTube
discussed
10:0431,490 views1,434 likes179 commentsnot applicableField context

Video summary pending.

GlyNAC: The Secret to Longevity? - YouTube
low signal
2:23179 views9 likes0 commentsnot applicableField context

Video summary pending.

Latest Research: These 2 Supplements Reversed Cognitive Decline
discussed
9:4232,195 views1,354 likes140 commentsnot applicableField context

Video summary pending.

Fasting Isn't Enough—Your Mitochondria Need This - YouTube
discussed
7:1079,355 views4,221 likes316 commentsnot applicableField context

Video summary pending.

Glycine & NAC: Can They Transform The Way We Age? [2023]
discussed
20:06122,008 views4,285 likes467 commentsnot applicableField context

Video summary pending.

Banned! Why is NAC Getting Removed from Shelves?
discussedmixed
12:23250,485 views6,675 likes1,694 commentsreadyField context

This video provides field-context commentary on NAC rather than direct evaluation of Team GlyNAC, explaining NAC as a cysteine precursor that can raise glutathione and support antioxidant defenses. The speaker emphasizes that NAC has real pharmacologic history, especially in hospital use for acetaminophen toxicity and liver-related applications, which supports biological plausibility. At the same time, they argue the FDA controversy is tied to drug-versus-supplement classification and exaggerated supplement marketing claims, not necessarily proof that NAC is ineffective. The overall framing is cautious: NAC is treated as potentially useful and scientifically interesting, but not as a clearly transformative longevity intervention with strong hard-outcome human evidence.

Key takeaways
  • The video reinforces the core GlyNAC/NAC mechanism by describing NAC as a glutathione-supporting cysteine precursor tied to oxidative-stress biology.
  • It highlights NAC’s established medical use, which strengthens plausibility that the compound has genuine biological effects rather than being a purely speculative supplement.
  • The speaker notes that accessible evidence discussed is mostly small studies, biomarker improvements, and clinical utility claims, not large durable trials showing major aging or longevity outcomes.
  • Regulatory scrutiny is framed mainly as a drug-versus-supplement and claims-policing issue, which is relevant context for any translational project built around NAC-related supplementation.
  • The speaker explicitly tempers expectations, suggesting NAC is unlikely to be dramatic or essential for most consumers, which weakens any strong investment-style enthusiasm.
  • Because this is a third-party explainer with substantial audience engagement, it is useful as public field-context evidence about perception of NAC, but not as direct validation of Team GlyNAC’s clinical promise.
Beta lactam antibiotics: cell wall: Mode of action: Antibiotic lecture 3 part A
unwatchedneutral
24:1046 views1 likes0 commentsreadyField context

This video is a generic instructional lecture on beta-lactam antibiotics and their mechanism of action, not a discussion of Team GlyNAC or longevity research. It explains the shared beta-lactam ring structure across antibiotic subclasses and focuses on how these drugs inhibit penicillin-binding proteins involved in peptidoglycan cross-linking. The lecture also reviews bacterial cell wall structure in gram-positive and gram-negative organisms and describes how blocking cross-linking weakens the wall and can cause osmotic lysis. As a result, the video provides only very broad biomedical field context and no direct evidence about the GlyNAC project itself.

Key takeaways
  • The video is about beta-lactam antibiotic pharmacology, not Team GlyNAC or GlyNAC supplementation.
  • It explains that beta-lactams inhibit penicillin-binding proteins/transpeptidases that cross-link peptidoglycan in bacterial cell walls.
  • The lecture describes how failed cross-linking weakens the wall and can lead to bacterial swelling and lysis.
  • It distinguishes gram-positive bacteria as having thicker peptidoglycan layers than gram-negative bacteria.
  • For project-rating purposes, this is at most weak field-context material and does not add project-specific support or criticism.
Why do people take GlyNAC?
low signalfavorable
3:17160 views6 likes0 commentsreadyField context

This short video presents GlyNAC as a longevity-oriented supplement strategy combining glycine and N-acetylcysteine to raise glutathione and improve mitochondrial and oxidative-stress-related aging defects. The speaker highlights reported benefits from older-adult studies, including improvements in metabolic markers, insulin sensitivity, physical performance, muscle strength, memory, and cognition, while also describing the supplement as generally well tolerated. The video also references animal findings such as lifespan extension and broader anti-aging effects, but the transcript does not clearly separate preclinical from human evidence or provide much sourcing detail. Overall, it functions more as a promotional overview of GlyNAC’s promise than as a balanced review of the project’s evidentiary limits.

Key takeaways
  • Frames GlyNAC as a potentially safe, practical longevity supplement aimed at boosting glutathione.
  • Claims benefits for oxidative stress, mitochondrial function, inflammation, and metabolic health.
  • References small human studies in older adults reporting gains in insulin sensitivity, strength, physical performance, memory, and cognition.
  • Mentions animal-study lifespan and broader anti-aging benefits without much citation context.
  • Notes typical dosing around 10-15 g/day with mostly mild gastrointestinal side effects.
How Does NAC (N-Acetylcysteine) Work
discussedneutral
2:54451,430 views19,034 likes1,044 commentsreadyField context

This video appears to be a general explainer about NAC rather than a direct evaluation of Team GlyNAC, and the available transcript evidence is too garbled to extract substantive claims. The only clear signal from the transcript chunk is that NAC is mentioned, but no coherent mechanism, efficacy claim, safety discussion, or study result can be verified from the provided text. As a result, the video offers only weak field-context relevance for the project and does not materially strengthen or weaken the case for GlyNAC. Although audience engagement is high, the transcript quality here makes the content itself unreliable as evidence.

Key takeaways
  • The provided transcript chunk is largely unintelligible and does not support confident claim extraction.
  • NAC is mentioned, but no clear explanation of mechanism, benefit, risk, or study outcome is recoverable.
  • The video is only field-context relevant to Team GlyNAC, not usable as direct project evidence from this chunk alone.
  • No project-specific efficacy, credibility, or translational milestone can be inferred from the available text.
  • High audience discussion suggests public interest, but poor transcript quality makes this weak evidentiary input.
GlyNAC: A promising longevity intervention - but far earlier and narrower than most people think.
low signalfavorable
34:20126 views4 likes1 commentsreadyField context

This video presents GlyNAC as a plausible, mechanistically grounded longevity intervention rather than a cosmetic anti-aging supplement claim. It centers on the idea that aging-related declines in glutathione synthesis, driven by limited glycine and cysteine availability, contribute to oxidative stress and mitochondrial dysfunction, and that combining glycine with N-acetylcysteine may help restore that system. The speaker emphasizes small randomized and pilot human studies plus broader biochemical rationale to argue that GlyNAC is more credible than NAC or glycine alone. At the same time, the case presented remains early-stage and focused on biomarkers and limited functional outcomes rather than durable clinical or lifespan evidence.

Key takeaways
  • GlyNAC is framed as a two-part precursor strategy intended to raise intracellular glutathione, not as direct glutathione supplementation.
  • The transcript argues that older adults may have substantially lower glutathione and higher oxidative-stress markers, providing the biological rationale for intervention.
  • NAC alone is described as useful in acute medical contexts but insufficient as a standalone chronic aging intervention.
  • Glycine alone is also presented as inadequate, with the speaker arguing that both substrates are needed together for the proposed effect.
  • The evidence discussed is presented as promising but still narrow, relying on mechanistic logic and small early human studies rather than hard long-term outcomes.
Practical Glycation Busters and Supplements with Dr. Paul Reynolds
low signalfavorable
23:29804 views88 likes9 commentsreadyField context

This video presents GlyNAC as one practical component of a broader anti-glycation and healthy-aging supplement strategy rather than as a standalone breakthrough. The speaker cites Baylor College of Medicine-linked older-adult studies to argue that glycine plus NAC can restore glutathione, reduce oxidative stress and inflammation, improve mitochondrial function, and lower insulin resistance, but the discussion remains focused on early human biomarker findings rather than hard clinical outcomes. GlyNAC is grouped alongside other supplements and lifestyle measures, with glucose control framed as the primary anti-glycation intervention. Overall, the segment is educational but strongly promotional, mixing evidence references with product-style recommendations and affiliate-link framing.

Key takeaways
  • GlyNAC is portrayed favorably as a glutathione-restoring, oxidative-stress-lowering supplement relevant to aging biology and glycation control.
  • The speaker explicitly leans on Baylor-associated human studies, but the support described is still early-stage, small-sample, and biomarker-heavy.
  • The video does not provide a direct project update, new trial results, or rigorous scrutiny of Team GlyNAC specifically.
  • GlyNAC is positioned as one element of a broader stack that also includes lifestyle glucose control and other supplements such as L-carnosine, B vitamins, ketones, allulose, and yerba mate.
  • The tone is promotional and practical, with supplement guidance and affiliate-style framing outweighing analytical evaluation.
  • Audience reception is low signal, so this video offers weak external validation regardless of its favorable framing.
GlyNac (Glycine NAC) Supplementation: Advancing Cellular Health Through Scientific Insights
discussedfavorable
19:5030,792 views1,168 likes105 commentsreadyField context

This video presents GlyNAC as a promising longevity-oriented supplementation strategy centered on glycine plus N-acetylcysteine to raise glutathione, reduce oxidative stress, and support mitochondrial function. The speaker highlights a small older-adult human study and broader mechanistic arguments, extending the discussion to inflammation, endothelial function, insulin resistance, cognition, strength, gait, and body composition, while also claiming potential benefits for athletic recovery and immune support. The content repeatedly expands beyond direct project evidence into general glutathione-support tactics such as sulfur-rich foods, vitamin C, selenium, alpha lipoic acid, whey protein, and probiotics. Overall, the video is informative for field context but leans heavily on early-stage human data, preclinical framing, and supplement advocacy rather than balanced assessment of unresolved clinical questions.

Key takeaways
  • Frames GlyNAC as a glutathione-restoring intervention with potential relevance to oxidative stress, mitochondrial health, and aging-related decline.
  • Relies substantially on a small early-stage human study plus mechanistic reasoning rather than large, durable clinical evidence.
  • Claims possible benefits across multiple domains including inflammation, insulin resistance, cognition, physical performance, immune support, and recovery.
  • Extends the discussion into a broader glutathione-support stack, including diet and companion supplements, which dilutes direct evidence specific to GlyNAC itself.
  • Includes cautionary language about consulting clinicians and needing more research, but the overall presentation remains strongly pro-supplement.
  • Useful as field-context signal for how GlyNAC is being discussed publicly, but weak as independent validation of project efficacy.
Glycine + N-Acetyl Cysteine Supplementation Increases Lifespan
discussedfavorable
10:0592,515 views3,200 likes358 commentsreadyField context

This video presents GlyNAC as a promising longevity intervention by arguing that age-related glutathione decline contributes to aging and that supplementing glycine plus N-acetylcysteine can reverse some of that decline. It highlights small human studies in older adults reporting improvements across oxidative stress, inflammation, insulin resistance, mitochondrial function, body composition, strength, exercise capacity, cognition, and related biomarkers. It also leans on a mouse study reporting increased median lifespan and tissue glutathione restoration, plus centenarian comparisons showing higher glutathione and precursor-related signals than a younger older-adult group. Overall, the video is supportive of the GlyNAC hypothesis, but the evidence presented is still early-stage, with human data limited by small studies and the animal lifespan result not resolving potential calorie-intake confounding.

Key takeaways
  • The video frames glutathione decline as an important aging mechanism and GlyNAC as a practical way to restore it.
  • It cites small human studies, including randomized older-adult work, reporting favorable biomarker and some functional changes, but these remain early and limited evidence.
  • The strongest longevity-specific claim comes from mouse data showing longer median lifespan, though key confounders such as food intake and body weight were not fully addressed.
  • Centenarian comparisons are used to support the broader glutathione-longevity narrative, but they are associative rather than causal evidence.
  • The presentation is more biohacking-forward than clinically cautious, with only brief acknowledgment of study limitations.
  • Audience reception was discussed and substantial, so while engagement does not validate the claims, it makes the video more relevant as field-context signal than a low-view promotional artifact.
NAC & Glutathione for Aging, Longevity
discussedfavorable
5:2318,726 views1,158 likes171 commentsreadyField context

This video presents GlyNAC as a longevity-oriented supplementation strategy combining glycine and N-acetylcysteine to raise intracellular glutathione and address oxidative stress and mitochondrial dysfunction associated with aging. The speaker cites Baylor-associated and other human studies as suggesting short-term improvements in biomarkers, waist circumference, exercise capacity, and multiple hallmarks of aging over roughly 8 weeks. The video also argues that GlyNAC may be more practical than direct glutathione supplementation because it supports endogenous production, may be less expensive, and could add glycine-related sleep benefits. Overall, it functions more as an enthusiastic explainer and supplement recommendation than as a balanced review of the evidence base.

Key takeaways
  • Frames GlyNAC as a glutathione-boosting intervention relevant to aging and longevity.
  • Highlights small human and Baylor-linked studies reporting short-term biomarker and functional improvements.
  • Argues precursor supplementation may outperform direct glutathione by improving intracellular, tissue-specific production.
  • Emphasizes practical consumer advantages including cost, established NAC familiarity, and possible sleep benefits from glycine.
  • Uses promotional, product-oriented framing and does not substantially engage with evidence limitations, durability, or unresolved clinical outcomes.
Glutathione Restoration Improves Hallmarks Of Aging in Older Adults
discussedfavorable
15:2938,157 views1,770 likes276 commentsreadyField context

The video presents GlyNAC as a mechanistically grounded intervention aimed at reversing age-related glutathione deficiency and improving multiple hallmarks of aging. The speaker describes small older-adult studies in which glycine plus N-acetylcysteine supplementation restored glutathione toward younger levels and was associated with improvements in oxidative stress, inflammation, mitochondrial function, insulin sensitivity, and some physical and cognitive measures. A recurring point is that several benefits moved back toward baseline after supplementation stopped, which the speaker interprets as evidence of a treatment effect. Overall, the video supports Team GlyNAC's thesis, but the evidence discussed is still early-stage, biomarker-heavy, and based on small cohorts rather than durable clinical outcomes.

Key takeaways
  • The core claim is that GlyNAC replenishes glutathione in older adults by supplying glycine and cysteine precursors.
  • Reported benefits include reduced oxidative damage and inflammation plus improved mitochondrial metabolism, fat oxidation, glucose handling, and insulin sensitivity.
  • The speaker argues that post-supplementation reversal strengthens the case that GlyNAC caused the observed changes.
  • The evidence presented is mainly small, short-duration human studies supported by mechanistic reasoning rather than large clinical trials.
  • The video is relevant as field context because it reinforces the project's biological rationale while not resolving durability, safety, or hard endpoint questions.
The Best Anti-Aging Supplement - GlyNAC Reverse Aging
low signalfavorable
5:4792 views8 likes0 commentsreadyField context

This video presents GlyNAC as a strong anti-aging supplement and describes it as a glycine plus N-acetylcysteine combination that may raise glutathione and improve oxidative stress, inflammation, mitochondrial function, and insulin sensitivity. The speaker also extends the claimed benefits to endothelial function, exercise capacity, and sexual function, while suggesting the intervention may be most useful for older adults or people with chronic inflammation. At the same time, the summary is largely built on broad positive interpretation, anecdotal framing, and informal self-experimentation advice rather than careful discussion of evidentiary limits. The video aligns with the project’s core thesis, but it does not materially strengthen the case because it is promotional in tone and offers weak independent validation.

Key takeaways
  • Strongly endorses GlyNAC as a leading anti-aging supplement centered on glutathione support.
  • Links GlyNAC to reduced oxidative stress, lower inflammation, improved mitochondrial function, and better insulin sensitivity.
  • Claims possible practical benefits for vascular function, exercise capacity, and sexual function.
  • Suggests benefits may be concentrated in older adults or people with chronic inflammation.
  • Notes effects may fade after discontinuation, implying durability is uncertain.
  • Provides informal dosing suggestions, reinforcing the video’s anecdotal and self-experimentation-oriented framing.
Glycine + NAC "GlyNAC" benefits: From Slowing Aging to Better Sleep
moderatefavorable
5:422,782 views81 likes5 commentsreadyField context

This video presents GlyNAC as a promising healthy-aging supplement strategy built from glycine plus N-acetylcysteine, with emphasis on boosting glutathione, lowering oxidative stress, and supporting mitochondrial function. The speaker highlights sleep as a major benefit area, claiming glycine may help people fall asleep faster while NAC may support circadian regulation. The video also extends the claimed benefits to cognition, immunity, digestion, skin, muscle maintenance, insulin sensitivity, and mood, framing GlyNAC as a broad wellness intervention rather than a narrow therapeutic tool. Overall, it aligns with the project’s core narrative but does so in a simplified, consumer-facing way with little discussion of evidence quality, study size, or unresolved clinical questions.

Key takeaways
  • The video strongly reinforces the project’s central mechanism narrative around glutathione support, oxidative stress reduction, and mitochondrial health.
  • Sleep improvement is a primary angle, making the content relevant to broader consumer interest beyond longevity science alone.
  • The speaker expands GlyNAC’s possible benefits across many domains, including cognition, metabolism, immunity, skin, digestion, and muscle preservation.
  • The framing is educational-marketing oriented and encourages supplement consideration, while only lightly acknowledging the need to consult a clinician.
  • For project evaluation, the video is more useful as field-level awareness and positioning evidence than as rigorous support for clinical effectiveness.
Can Glycine Turn Off Inflammation: Hype or Real Results?
duration unknownunavailableField context

Transcript unavailable.

Unlocking Youth: Glycine, NAC, and the Secrets of Age Reversal
low signalfavorable
3:07530 views46 likes0 commentsreadyField context

This video presents GlyNAC as a longevity-oriented supplementation strategy built around glycine and NAC to increase glutathione and reduce oxidative stress. The speaker describes glutathione as a major antioxidant involved in tissue protection and regeneration of vitamins C and E, and frames higher glutathione as supportive of healthier aging. Glycine is also presented as important for collagen, connective tissue, gut lining, and other repair-related functions, reinforcing the overall anti-aging pitch. The transcript is educational in tone but strongly promotional, with broad claims about age reversal and optimal aging made without visible discussion of study quality, limitations, or risks.

Key takeaways
  • The speaker portrays NAC as a cysteine source that helps raise glutathione levels.
  • Glycine is framed as both a glutathione building block and a structural amino acid important for collagen and connective tissue.
  • The video links oxidative stress reduction and higher glutathione to better aging outcomes and protection from cellular damage.
  • Dietary sources such as nuts, seeds, eggs, meat, bone broth, and collagen-rich tissues are highlighted as relevant inputs.
  • The overall message is that combining glycine and NAC may support 'optimal aging' or age reversal, but the transcript does not substantively address evidence gaps or uncertainties.
NAC and Glutathione - YouTube
duration unknownunavailableField context

Transcript unavailable.

Vitamin D, Glutathione & NAC: new relationships you should know
discussedfavorable
22:47305,679 views13,749 likes1,072 commentsreadyField context

This video presents a broad, strongly pro-glutathione case that aligns with the general scientific narrative behind GlyNAC: aging, oxidative stress, mitochondrial dysfunction, and low glutathione are framed as interconnected problems that may be improved through NAC, glycine, diet, exercise, fasting, and vitamin D optimization. Across the chunks, the speaker repeatedly argues that glutathione depletion is common in older adults and relevant to cardiometabolic, liver, neurodegenerative, and infectious-disease risk, while suggesting NAC plus glycine as a practical way to support glutathione synthesis. However, the discussion stays mostly at the level of mechanism, observational associations, and health-optimization advice rather than rigorous evaluation of GlyNAC-specific clinical evidence. It is therefore useful as field-context signal for public enthusiasm around glutathione/NAC concepts, but weak as evidence for Team GlyNAC’s therapeutic validity because it is promotional, supplement-forward, and not a balanced review of human outcomes.

Key takeaways
  • The speaker strongly reinforces the core GlyNAC premise that glutathione depletion contributes to aging-related dysfunction and that NAC plus glycine may help restore it.
  • Glutathione is framed as central to mitochondrial function, oxidative-stress defense, liver health, and resilience against age-related disease processes.
  • Vitamin D, GGT, and glutathione-related testing are presented as practical tools for assessing need, though the discussion is more heuristic than evidence-driven.
  • The content relies heavily on mechanistic and observational reasoning, with little emphasis on hard clinical endpoints, durability, or unresolved safety questions.
  • Commercial supplement promotion is mixed directly into the educational content, which lowers evidentiary weight despite the large and active audience reception.
  • For Team GlyNAC, this video is best treated as ecosystem validation that the glutathione/NAC story resonates publicly, not as strong independent support for the project itself.
NAC, Glutathione & Aging: New Study is Impressive
discussedfavorable
11:49422,269 views16,836 likes1,389 commentsreadyField context

This video presents GlyNAC in strongly positive terms as a practical way to raise glutathione by supplying glycine and NAC rather than taking glutathione directly. The speaker highlights a small open-label study in older adults that reportedly showed improvements in oxidative stress, mitochondrial and metabolic measures, body composition, and energy over roughly eight weeks. They also frame GGT and ALT as simple blood markers that could identify people who might benefit from GlyNAC, and extend the discussion to liver stress, aging, and other broad health contexts. Overall, the video gives useful field context on how GlyNAC is being interpreted in longevity circles, but it leans heavily on early-stage evidence and includes an explicit product-promotion angle.

Key takeaways
  • Frames GlyNAC as a more effective glutathione-support strategy than direct glutathione supplementation because it provides the precursors for endogenous synthesis.
  • Emphasizes a small early-stage older-adult study as evidence for benefits across oxidative stress, mitochondrial function, metabolism, body composition, and subjective energy.
  • Presents GGT and ALT, especially values above about 30, as practical screening markers for possible glutathione insufficiency or oxidative burden.
  • Extends the relevance of GlyNAC to aging, liver stress, alcohol or acetaminophen exposure, and other oxidative-stress-related conditions, broadening the claim set beyond the core evidence.
  • Includes supplement-use advice such as timing doses in the evening, reflecting a recommendation-heavy and consumer-oriented framing.
  • Contains a commercial promotion component, which reduces its evidentiary weight as an objective assessment of the project.
Glycine for Longevity: Antioxidant Combination You ACTUALLY Need
moderatefavorable
9:193,307 views143 likes12 commentsreadyField context

This video presents GlyNAC as a longevity-oriented supplementation strategy built from glycine and N-acetylcysteine to raise glutathione and reduce oxidative stress. The speaker emphasizes proposed benefits for mitochondrial function, inflammation, insulin resistance, endothelial function, and muscle strength, drawing on animal studies, reviews, and small human trials. Glycine is also framed as independently beneficial for cardiometabolic and anti-inflammatory health through its role in glutathione synthesis and related pathways. Overall, the video is supportive of GlyNAC’s promise, but the evidence discussed is still largely early-stage and does not resolve long-term safety, durability, or hard clinical outcomes.

Key takeaways
  • GlyNAC is described as a glycine plus NAC combination intended to boost glutathione production.
  • The video links GlyNAC to lower oxidative stress and better mitochondrial and inflammatory aging markers.
  • Claimed benefits include possible improvements in insulin resistance, endothelial function, and muscle strength.
  • Glycine alone is portrayed as potentially supportive for cardiovascular, metabolic, and nervous-system health.
  • Most of the supporting evidence cited is preclinical, review-based, genetic/association-based, or from small human studies rather than large definitive trials.
Anti-Aging with GlyNAC (Glycine + NAC) to make Glutathione
discussedfavorable
6:10233,435 views8,488 likes576 commentsreadyField context

This video presents GlyNAC as a promising anti-aging supplementation strategy that combines glycine and N-acetylcysteine to raise glutathione and counter oxidative-stress and mitochondrial dysfunction associated with aging. The speaker highlights a small August 2022 older-adult study reporting improvements across biomarkers and some functional measures, including strength, walking speed, blood pressure, inflammation, insulin resistance, endothelial function, and cellular aging markers. He also argues GlyNAC may work better than direct glutathione supplementation for some patients, while noting his clinic sometimes uses both approaches in sicker individuals. Although the overall framing is strongly optimistic, the speaker does acknowledge that the human evidence base remains early-stage and that larger, more definitive studies are still needed.

Key takeaways
  • Frames GlyNAC as a glutathione-restoring intervention aimed at oxidative stress, mitochondrial dysfunction, and age-related decline.
  • Cites a small 16-week older-adult study as evidence for improvements in both biomarkers and functional outcomes.
  • Emphasizes reported gains in muscle strength, gait speed, blood pressure, inflammation, insulin resistance, and endothelial function.
  • Contrasts GlyNAC with direct glutathione supplementation and suggests GlyNAC may be more effective for raising glutathione indirectly.
  • Includes speaker dosing recommendations, but these appear to reflect clinical opinion rather than a definitive standardized protocol.
  • Acknowledges the evidence is still limited by small sample sizes and lack of large, definitive human trials.

Evidence

news (14)
paper (19)
Supplementing Glycine and N-Acetylcysteine (GlyNAC) in Older Adults Improves Glutathione Deficiency, Oxidative Stress, Mitochondrial Dysfunction, Inflammation, Physical Function, and Aging Hallmarks: A Randomized Clinical Trial.
Field contextfetched
https://pubmed.ncbi.nlm.nih.gov/35975308/
pmc5/22/202613,795 chars
GlyNAC (Glycine and N-Acetylcysteine) Supplementation in Old Mice Improves Brain Glutathione Deficiency, Oxidative Stress, Glucose Uptake, Mitochondrial Dysfunction, Genomic Damage, Inflammation and Neurotrophic Factors to Reverse Age-Associated Cognitive Decline: Implications for Improving Brain Health in Aging.
Field contextfetched
https://pubmed.ncbi.nlm.nih.gov/37237908/
pmc5/22/2026235,429 chars
GlyNAC (Glycine and N-Acetylcysteine) Supplementation in Old Mice Improves Brain Glutathione Deficiency, Oxidative Stress, Glucose Uptake, Mitochondrial Dysfunction, Genomic Damage, Inflammation and Neurotrophic Factors to Reverse Age-Associated Cognitive Decline: Implications for Improving Brain Health in Aging
Field contextskipped_snippet_only
https://www.mdpi.com/2076-3921/12/5/1042/pdf?version=1683187259
openalex_abstract5/22/20261,516 chars
A Randomized Controlled Clinical Trial in Healthy Older Adults to Determine Efficacy of Glycine and N-Acetylcysteine Supplementation on Glutathione Redox Status and Oxidative Damage.
Field contextfetched
https://pubmed.ncbi.nlm.nih.gov/35821844/
pmc5/22/2026133,017 chars
GlyNAC (Glycine and N-Acetylcysteine) Supplementation Improves Impaired Mitochondrial Fuel Oxidation and Lowers Insulin Resistance in Patients with Type 2 Diabetes: Results of a Pilot Study.
Field contextfetched
https://pubmed.ncbi.nlm.nih.gov/35052658/
europepmc5/22/2026124,445 chars
GlyNAC (Glycine and N-Acetylcysteine) Supplementation in Mice Increases Length of Life by Correcting Glutathione Deficiency, Oxidative Stress, Mitochondrial Dysfunction, Abnormalities in Mitophagy and Nutrient Sensing, and Genomic Damage.
Field contextfetched
https://pubmed.ncbi.nlm.nih.gov/35268089/
pmc5/22/2026133,683 chars
Supplementing glycine and N-acetylcysteine (GlyNAC) rapidly improves health-related quality of life and lowers perception of fatigue in patients with HIV.
Field contextfetched
https://pubmed.ncbi.nlm.nih.gov/34185721/
europepmc5/22/202615,844 chars
Severe Glutathione Deficiency, Oxidative Stress and Oxidant Damage in Adults Hospitalized with COVID-19: Implications for GlyNAC (Glycine and N-Acetylcysteine) Supplementation.
Field contextfetched
https://pubmed.ncbi.nlm.nih.gov/35052554/
pmc5/22/2026107,387 chars
Glycine and N-acetylcysteine (GlyNAC) supplementation in older adults improves glutathione deficiency, oxidative stress, mitochondrial dysfunction, inflammation, insulin resistance, endothelial dysfunction, genotoxicity, muscle strength, and cognition: Results of a pilot clinical trial.
Field contextfetched
https://pubmed.ncbi.nlm.nih.gov/33783984/
pmc5/22/2026213,526 chars
GlyNAC Supplementation Improves Glutathione Deficiency, Oxidative Stress, Mitochondrial Dysfunction, Inflammation, Aging Hallmarks, Metabolic Defects, Muscle Strength, Cognitive Decline, and Body Composition: Implications for Healthy Aging.
Field contextfetched
https://pubmed.ncbi.nlm.nih.gov/34587244/
europepmc5/22/202613,064 chars
Supplementing Glycine and N-acetylcysteine (GlyNAC) in Aging HIV Patients Improves Oxidative Stress, Mitochondrial Dysfunction, Inflammation, Endothelial Dysfunction, Insulin Resistance, Genotoxicity, Strength, and Cognition: Results of an Open-Label Clinical Trial.
Field contextfetched
https://pubmed.ncbi.nlm.nih.gov/33007928/
europepmc5/22/2026184,171 chars
patent (56)
project page (7)
Team GlyNAC
Project specificfetched
https://bcm.edu
direct5/22/20268,413 chars
video (28)
web (7)
wiki (22)

★ AI estimate from available evidence — click any star for rationale.